Clinical Trial Update: Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating the efficacy and safety of empagliflozin versus placebo and sitagliptin over 24 weeks in adults with type 2 diabetes; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2014-06-16